SEARCH

SEARCH BY CITATION

References

  • 1
    Stearn EW, Stearn AE. The Effect of Smallpox on the Destiny of the Amerindian. Boston, MA: Bruce Humphries; 1945.
  • 2
    Alibek K. Biohazard. New York NY: Random House; 1999.
  • 3
    Henderson DA, Inglesby TV, Bartlett JG et al. Smallpox as a biological weapon. medical and public health management. Working Group on Civilian Biodefense. JAMA 1999; 281: 21272137.
  • 4
    Henderson DA. Countering the posteradication threat of smallpox and polio. Clin Infect Dis 2002; 34: 7983.
  • 5
    Slater PE, Anis E, Leventhal A. Preparation for an outbreak of smallpox in Israel. Isr Med Assoc J 2002; 4: 507512.
  • 6
    CDC. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. Morb Mortal Wkly Rep 2002; 50 (RR10): 125.
  • 7
    Brundtland GH. Statement to the press by the director general of the World Health Organization: updated guidance on smallpox vaccination. October 2, 2001. Geneva: World Health Organization; 2001.
  • 8
    Breman JG. Diagnosis and management of smallpox. [Comment]. N Engl J Med Online 2002; 346: 13231325.
  • 9
    Albert MR, Ostheimer KG, Liewehr DJ, Steinberg SM, Breman JG. Smallpox manifestations and survival during the Boston epidemic of 1901–03. Ann Intern Med Online 2002; 137: 9931000.
  • 10
    Henderson DA. Smallpox: clinical and epidemiologic features. [comment]. Emerg Infect Dis 1999; 5: 540546.
  • 11
    Franz DR, Jahrling PB, McClain DJ et al. Clinical recognition and management of patients exposed to biological warfare agents. Clin Lab Med 2001; 21: 435473.
  • 12
    Dixon CW. Smallpox. London: J & A Churchill Ltd; 1962.
  • 13
    Henderson DA. Smallpox: clinical and epidemiologic features. Med Health R I 2002; 85: 107108.
  • 14
    Rao AR. Smallpox. Bombay: Kothari Book Depot; 1972.
  • 15
    Mehta BC, Doctor RG, Purandare NM, Patel JC. Hemorrhagic smallpox. A study of 22 cases to determine the cause of bleeding. Indian J Med Sci 1967; 21: 518523.
  • 16
    Mitra M, Bhattacharya DK. Some observations on haemorrhagic smallpox (Type I). J Indian Med Assoc 1976; 67: 237240.
  • 17
    Downie AW, Fedson DS, Saint Vincent L, Rao AR, Kempe CH. Haemorrhagic smallpox. J Hyg 1969; 67: 619629.
  • 18
    Martin DB. The cause of death in smallpox: an examination of the pathology record. Mil Med 2002; 167: 546551.
  • 19
    Koplan JP, Foster SO. Smallpox: clinical types, causes of death, and treatment. J Infect Dis 1979; 140: 440441.
  • 20
    De Clercq E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin Microbiol Rev 2001; 14: 382397.
  • 21
    Larsson M, Fonteneau JF, Somersan S et al. Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells.[erratum appears in Eur J Immunol 2002; 32 (1): 307]. Eur J Immunol 2001; 31: 34323442.
  • 22
    Yang S, Kittlesen D, Slingluff CL Jr, Vervaert CE, Seigler HF, Darrow TL. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3. J Immunol 2000; 164: 42044211.
  • 23
    Vanderplasschen A, Hollinshead M, Smith GL. Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. J Gen Virol 1997; 78: 20412048.
  • 24
    Di Nicola M, Siena S, Bregni M et al. Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors. Cancer Gene Ther 1998; 5: 350356.
  • 25
    Drillien R, Spehner D, Bohbot A, Hanau D. Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes. Virology 2000; 268: 471481.
  • 26
    Engelmayer J, Larsson M, Subklewe M et al. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J Immunol 1999; 163: 67626768.
  • 27
    Avery RK, Ljungman P. Prophylactic measures in the solid-organ recipient before transplantation. Philos Trans R Soc Lond B Biol Sci 2001; 356: 957977.
  • 28
    Asanuma H, Rinki M, Sharp M et al. Immunisations in solid-organ transplant recipients. N Engl J Med 2002; 347: 2634.
  • 29
    Stark K, Gunther M, Schonfeld C, Tullius SG, Bienzle U. Immunisations in solid-organ transplant recipients. Lancet 2002; 359: 957965.
  • 30
    Burroughs M, Moscona A. Immunization of pediatric solid organ transplant candidates and recipients. Clin Infect Dis 2000; 30: 857869.
  • 31
    Pirofski LA, Casadevall A. Use of licensed vaccines for active immunization of the immunocompromised host. Clin Microbiol Rev 1998; 11: 126.
  • 32
    LaRussa P, Steinberg S, Gershon AA. Varicella vaccine for immunocompromised children: results of collaborative studies in the United States and Canada. J Infect Dis 1996; 174 (Suppl. 3): S320S323.
  • 33
    Zamora I, Simon JM, Da Silva ME, Piqueras AI. Attenuated varicella virus vaccine in children with renal transplants. Pediatr Nephrol 1994; 8: 190192.
  • 34
    Sharrar RG, LaRussa P, Galea SA et al. The postmarketing safety profile of varicella vaccine. Vaccine 2000; 19: 916923.
  • 35
    Asanuma H, Rinki M, Sharp M et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med Online 2002; 347: 2634.
  • 36
    Ljungman P, Duraj V, Magnius L. Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant 1991; 7: 8993.
  • 37
    King SM, Saunders EF, Petric M, Gold R. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. Bone Marrow Transplant 1996; 17: 633636.
  • 38
    Kimball P, Verbeke S, Flattery M, Rhodes C, Tolman D. Influenza vaccination does not promote cellular or humoral activation among heart transplant recipients. Transplantation 2000; 69: 24492451.
  • 39
    Sepkowitz KA. How contagious is vaccinia? N Engl J Med 2003; 348: 18.
  • 40
    Frey SE, Newman FK, Cruz J et al. Dose-related effects of smallpox vaccine. N Engl J Med 2002; 346: 12751280.
  • 41
    Haim M, Gdalevich M, Mimouni D, Ashkenazi I, Shemer J. Adverse reactions to smallpox vaccine: the Israel Defense Force experience, 1991–96. A comparison with previous surveys. Mil Med 2000; 165: 287289.
  • 42
    Goldstein JA, Neff JM, Lane JM, Koplan JP. Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics 1975; 55: 342347.
  • 43
    Dick G. Smallpox: a reconsideration of public health policies. Prog Med Virol 1966; 8: 129.
  • 44
    Zagury D. Anti HIV cellular immunotherapy in AIDS. Lancet 1991; 338: 694695.
  • 45
    Read D, Neff J, Blumberg SJ, Stein RE, Sharp V, Newacheck PW et al. Contact vaccinia – transmission of vaccinia from smallpox vaccination. Ambulatory Pediatrics 2002; 2: 4957.
  • 46
    Neff JM, Levine RH, Lane JM et al. Complications of smallpox vaccination United States 1963. II. Results obtained by four statewide surveys. Pediatrics 1967; 39: 916923.
  • 47
    Neff JM, Lane JM, Pert JH, Moore R, Millar JD, Henderson DA. Complications of smallpox vaccination. I. National survey in the United States, 1963. N Engl J Med 1967; 276: 125132.
  • 48
    Neff JM, Lane JM, Fulginiti VA, Henderson DA. Contact vaccinia – transmission of vaccinia from smallpox vaccination. JAMA 2002; 288: 19011905.
  • 49
    Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis 1970; 122: 303309.
  • 50
    Dixon MF. Progressive vaccinia complicating lymphosarcoma. J Pathol 1970; 100: 5367.
  • 51
    Dixon MF. Smallpox vaccination. Br Med J 1970; 2: 539.
  • 52
    Tignor GH, Kende M, Hanham CA. Chemotherapeutic prevention of complications caused by vaccinia virus-vectored immunogen. Ann N Y Acad Sci 1992; 653: 334343.
  • 53
    Kemper AR, Davis MM, Freed GL. Expected adverse events in a mass smallpox vaccination campaign. Effective Clinical Practice 2002; 5: 8490.
  • 54
    Sharp JC, Fletcher WB. Experience of anti-vaccinia immunoglobulin in the United Kingdom. Lancet 1973; 1 (7804): 656659.
  • 55
    Kesson AM, Ferguson JK, Rawlinson WD, Cunningham AL. Progressive vaccinia treated with ribavirin and vaccinia immune globulin. Clin Infect Dis 1997; 25: 911914.
  • 56
    Newman FK, Cruz J, Shelton WB et al. Smallpox vaccination policy – the need for dialogue. [Comment]. N Engl J Med 2002; 346: 12751280.
  • 57
    Fauci AS. Smallpox vaccination policy – the need for dialogue. [Comment]. N Engl J Med Online 2002; 346: 13191320.